Form 4: Spyre Therapeutics CFO Executes Stock Option Exercise

Spyre Therapeutics CFO Scott L. Burrows exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• CFO Scott L. Burrows exercised options for 7,500 shares of common stock at an exercise price of $14.50.
• Following the exercise, the CFO sold 7,500 shares in multiple transactions at weighted average prices ranging from $69.75 to $72.06.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
• The reporting person retains beneficial ownership of 97,994 shares of common stock, including 67,476 restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-planned 10b5-1 arrangement and represents standard executive financial management.

Positives

• The transaction was executed under a pre-established Rule 10b5-1 plan, indicating a systematic approach to equity management rather than reactive selling.
• The CFO maintains a significant equity stake of 97,994 shares, aligning interests with shareholders.

Negatives

• The transaction represents a reduction in the direct beneficial ownership of the CFO.

Risks

• Future vesting of remaining restricted stock units and options is contingent upon continued employment with the issuer.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a disclosure of individual insider equity transactions.

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by C-suite executives in the biotechnology sector are standard practice for liquidity and tax planning and generally do not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest regarding insider trading regulations.
• The volume of shares sold relative to the total holdings is consistent with typical executive compensation liquidation patterns.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• Future vesting of 67,476 restricted stock units scheduled for September 1, 2026 and September 1, 2027.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, CFO, Equity Compensation